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Background: Percutaneous mitral valve repair is an emerging treatment option for patients with significant mitral regurgitation (MR). In the 
EVEREST trials, one or two MitraClip devices were placed to reduce MR, as needed. We analyzed pre-procedural transesophageal echocardiograms 
(TEE) of 75 subjects who received 1 or 2 MitraClip devices in the EVEREST II High-Risk Registry to identify potential patho-anatomic predictors of the 
number MitraClips devices implanted.
Methods: TEEs were reviewed for etiology of MR and patho-anatomic features of the valve, valve apparatus, and the regurgitant jet. All 
measurements were made in triplicate at a core echocardiography laboratory by investigators blinded to outcomes.
Results: Twenty-nine subjects (39%) had 2 devices placed. Deployment of a second device was equivalent for degenerative MR and functional 
MR. In the overall group (n = 75), subjects with increased anterior leaflet thickness (p = 0.004) and increased regurgitant jet diameter at the level 
of the mitral valve (p = 0.02) were more likely to receive two devices. Among subjects with functional MR (n=43) a non-ischemic etiology was also 
associated with use of 2 devices (56% vs 19%, p=0.01).
Conclusion: In the EVEREST II High-Risk Registry cohort, patients with increased anterior mitral valve leaflet thickness and a broad regurgitant jet 
were more likely to receive two MitraClip devices. Patients with non-ischemic functional MR were also more likely to receive two MitraClip devices. 
Variable
Overall Group
(n= 75)
1 Mitraclip
(n = 46)
2 Mitraclips
(n = 29)
P value
MR etiology (%) 0.2
Functional 43 (57) 29 (67) 14 (33)
Degenerative 32 (43) 17 (53) 15 (47)
End systolic annular diameter (mm) 40.4±6.4 40.3±5.3 40.6±8.0 1.0
End diastolic annular diameter (mm) 40.0±6.0 39.6±4.5 40.8±7.7 0.6
Anterior leaflet thickness (mm) 2.6±1.0 2.3±0.6 3.0±1.3 0.004
Posterior leaflet thickness (mm) 2.5±0.6 2.5±0.6 2.6±0.6 0.2
Regurgitant jet diameter at valve (mm) 11.3±4.7 10.3±4.1 12.8±5.3 0.02
T test or Wilcoxon rank sum test performed for analysis of continuous variables. Fisher’s exact test performed for analysis of categorical variables.
